Clinical Trial: The Efficacy of Tislelizumab Combined With Albumin-bound Paclitaxel and Platinum-based Chemotherapy in Patients With KRAS-mutated Lung Cancer

U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07638878) titled 'The Efficacy of Tislelizumab Combined With Albumin-bound Paclitaxel and Platinum-based Chemotherapy in Patients With KRAS-mutated Lung Cancer' on June 05.

Brief Summary: To determine the optimal objective response rate (ORR) of tislelizumab combined with albumin-bound paclitaxel and platinum agents in patients with KRAS-mutant lung cancer who are ineligible for curative surgery

Study Start Date: Nov. 06, 2020

Study Type: OBSERVATIONAL

Condition: Lung Cancer (Locally Advanced or Metastatic)

Intervention: DRUG: tislelizumab in combination with nab-paclitaxel and platinum chemotherapy

Unresectable KRAS mutation-positive lung can...